Not yet recruitingObservationalLast updated Aug 13, 2026

Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.

Overview

ClinicalTrials.gov ID: NCT07763821
Lead Sponsor: Assiut UniversityOTHER
Brief Summary: This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
Study Type: Observational

Status

Study Record Dates

NCT03164720Unknown status

SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis

NCT06631404Recruiting

Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients

NCT04256577Unknown status

Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment

NCT03958851Unknown status

Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis

NCT07505576Not yet recruiting

Anti-alpha-actinin Antibodies and Lupus Nephritis Activity

NCT06228222Unknown status

Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.